Genenta Science SpA · NASDAQ:GNTA
Genenta Science SpA — Saentra Forge — Investor Presentation (March 2026)
21 slides from Genenta Science SpA's investor presentation, March 2026
Slide 1: Saentra Forge: Next-Generation Strategic Industrial Consolidator
SAENTRA FORGE The Next-Generation Strategic Industrial Consolidator in Biotech, Defense, Aerospace, National Security. © 2026 Saentra Forge. All rights reserved worldwide March 2026
Slide 2: Forward-Looking Statements and Other Notices
FORWARD-LOOKING STATEMENTS AND OTHER NOTICES Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of histor
Slide 3: Leadership
LEADERSHIP + 30 years of experience as Chief Financial Officer in various biopharmaceutical, Highly experienced executive with skills diagnostic, and life science companies, in strategic finance, restructuring and including Biological Dynamics, GenMark reorganization processes, internal Diagnostics
Slide 4: Next-Generation Strategic Industrial Consolidator
NEXT-GENERATION STRATEGIC INDUSTRIAL CONSOLIDATOR In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A. evolved into Saentra Forge (Nasdaq: SAEN) a next-generation strategic industrial consolidator focused on acquiring privately held businesses operating in nati
Slide 5: Saentra Forge Strategic Pillars
SAENTRA FORGE STRATEGIC PILLARS The Company will be organized around key synergistic pillars BIOTECHNOLOGY DEFENSE AEROSPACE NATIONAL SECURITY built through strategic majority acquisitions, creating a diversified platform. 5
Slide 6: Defense, Aerospace, National Security
• DEFENSE • AEROSPACE • NATIONAL SECURITY
Slide 7: Defense, Aerospace, National Security
DEFENSE, AEROSPACE, NATIONAL SECURITY Saentra Forge’s defense and advanced manufacturing pillar will be built through the acquisition of multiple privately held businesses operating across defense, aerospace and security sectors. Through this integration, the Company will seek to enhance these busin
Slide 8: ATC First Integration: Company Overview
ATC FIRST INTEGRATION: COMPANY OVERVIEW ▪ ATC “Armi Tattiche Custom” is an Italian company founded in 2019. ATC designs, engineers, and manufactures high- precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories. Through vertical integration of design and through fi
Slide 9: ATC Integration: Key Figures
ATC INTEGRATION: KEY FIGURES • Genenta has entered into a binding agreement according to which it will provide funding for ATC through a series of reserved capital increases, via a performance-based and staged acquisition to support operations with the ultimate goal of owning a controlling position
Slide 10: Biotechnology
€} Saentra Forge BIOTECHNOLOGY
Slide 11: Genenta: Developing a Potential First in Class Cell Therapy
GENENTA: DEVELOPING A POTENTIAL FIRST IN CLASS CELL THERAPY Temferon TM is a one-time cell therapy designed to break the tumor-induced Proprietary platform to immune suppression by enabling sustained targeted expression of therapeutic provide durable and payload inside the tumor microenvironment (TM
Slide 12: Survival Metrics in TEM-GBM Study Up to 3 Years
SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS Evaluable Patients Dosed with Temferon 25 Number of Patients survival > 1 year 19 (76%) Number of Patients survival > 2 years1 8 (32%) Number of Patients survival > 3 years 2 (8%) Survival rate at 1 and 2 years since first surgery compared favorably wi
Slide 13: Partnership to Take to the Next Stage
PARTNERSHIP TO TAKE TO THE NEXT STAGE The Company has reached key clinical milestones that it believes will now enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and
Slide 14: Harnessing the Power of Stem Cells While Incorporating miRNA
HARNESSING THE POWER OF STEM CELLS WHILE INCORPORATING miRNA Use TEMs as vehicles to deliver IFN-⍺ into the TME Tie2-Expressing Monocytes (TEMs) Circulate low frequency Recruited into tumors Tie2 P/E Interferon-𝛂 126T TEMs in blood Tie2 Tie2 IFN-𝛂 Reprogramming TEMs Vessels Nuclei De Palma et al…
Slide 15: Temferon Delivers IFN-α Within the Tumor Microenvironment
TEMFERON DELIVERS IFN-⍺ WITHIN THE TUMOR MICROENVIRONMENT Single Temferon treatment potentially renders solid tumors visible to the immune system Tie2 monocytes coupled with miRNA126 TEMFERON AT A GLANCE Temferon Infusion of enable targeted payload delivery inside TEMFERON frozen and stored transduc
Slide 16: Temferon: Overcoming Immuno-Oncology Barriers
TEMFERON: OVERCOMING IMMUNO-ONCOLOGY BARRIERS VIA TARGETED, TUMOR-AGNOSTIC IMMUNE ACTIVATION SELECTIVE DELIVERY DEMONSTRATED PREVENT ACTIVATE IMMUNE WITHIN THE TUMOR DURABILITY SYSTEMIC TOXICITY SYSTEM MICROENVIRONMENT Genenta cell-based CD14 Tie2 macrophages (TEMs) Peripheral Blood platform (IFN-⍺
Slide 17: Preliminary Clinical Data in uMGMT GBM
PRELIMINARY CLINICAL DATA IN µMGMT GBM • Detectable and expectedly very low levels of IFN-⍺ (pg/ml range) in plasma; • Manageable safety profile, with adverse events commonly associated with autologous stem cell transplantation and glioblastoma; SAFETY AND • No dose limiting toxicities observed to d
Slide 18: Pierluigi Paracchi, CEO
PIERLUIGI PARACCHI, CEO pierluigi.paracchi@saentra.com www.saentra.com Via dell’Annunciata 31 - 20121 Milan, Italy © 2026 Saentra Forge. All rights reserved worldwide
Slide 19: Appendix
APPENDIX © 2026 Saentra Forge. All rights reserved worldwide
Slide 20: Board of Directors
BOARD OF DIRECTORS Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotechs as well as large pharma Giacomo Paracchi is a business lawyer with companies. extensive experience as General Counsel Most recently, he
Slide 21: Financial Profile
FINANCIAL PROFILE Cash & cash equivalents and marketable securities1 $ 33 MM Expected cash runway2 More than 12 months Number of shares outstanding3 23.4 MM Average volume4 721K shares 1 – Estimated (unaudited) at December 31, 2025. 2 - The complete documentation with respect to the Mandatory Conver